RxDoctor Payments Data

Edwin Heist, MD

Cardiovascular Disease · Boston, MANPI 1255313334

Payments from drug & device makers

$113,489in general payments, 2019–2025

Across 146 payments — averaging $777.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$40K
  • Pfizer$32K
  • Biotronik Inc.$26K
  • Abbott$13K
  • Biosense Webster, Inc.$2K
  • Microport CRM USA Inc$1K
  • plus $35 from 1 others
$8,800in research payments, 2019–2025

Across 9 payments — averaging $977.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotronik Inc.$9K

What the payments were for

  • Consulting fees$74,88081%
  • Speaking & faculty fees$8,3759%
  • Travel & lodging$7,0088%
  • Food & beverage$1,7262%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific23$39,545
Pfizer37$32,455
Biotronik Inc.57$25,720
Abbott17$12,995
Biosense Webster, Inc.10$1,738
Microport CRM USA Inc1$1,000
Impulse Dynamics (USA) Inc.1$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$113,489 in reported general payments places this provider in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$450,972
Medicare patients
2,426
Services billed
4,699

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$142,870
XareltoRivaroxaban20$24,443
MultaqDronedarone Hcl20$18,815
Dofetilide12$5,483
Metoprolol Succinate72$2,121
Mexiletine Hcl12$1,340
Nadolol25$1,071
Flecainide Acetate11$401
Dilt-XrDiltiazem Hcl12$292
Atorvastatin Calcium12$277
Rosuvastatin Calcium11$241
Amlodipine Besylate13$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32,455$142,870105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →